# Most Revolutionary Track: Track C (Digital Twin Reactor)

Per the ISEF outline, **Track C** is the most revolutionary component of the platform.

## Key Innovations (Section 4.3 - Novelty)

The outline explicitly lists these as "first work" achievements, all within Track C:

1. **First** to include anisotropy + stromal feedback in 3D digital twin
2. **First** to train RL on mechanistic models with biomarker-driven stratification  
3. **First** to provide clinical decision rules (ρ > 0.024 day⁻¹ threshold → RL preferred)
4. The paper's one-liner conclusion: *"First end-to-end framework linking single-cell GRNs to RL adaptive therapy, with real-patient physics validation and actionable stratification rules."*

## Why Track C Is the Breakthrough

- **Integrative capstone**: Combines molecular insights (Track A) + spatial biophysics (Track B) into a clinically actionable pipeline
- **Real-patient validation credibility**: The 62-patient tensor comparison study (Figure 4) validates the core anisotropic modeling assumption directly on real patient data — this is positioned at the paper's start as the credibility-setting piece: *"Start strong: Real-patient validation study (Figure 4) ← this is your credibility"*
- **Tangible clinical benefit**: 13% cumulative drug reduction with equivalent tumor control (non-inferior time-to-progression)
- **Actionable stratification**: The proliferation rate biomarker (ρ > 0.024 day⁻¹) enables patient-specific therapy selection (>80% win rate in high-ρ tumors, vs 36.7% overall)
- **Mechanistic RL**: Policies trained on validated models outperform fixed schedules (RL 73.8 mm³ vs Stupp 137.8 mm³, 46.5% reduction, p=0.00067)

## Supporting Tracks

- **Track A** (Molecular → Spatial → Causal): Provides the GRN landscape, master switches (APOD, S100B, MT3), and invasion dynamics that parameterize Track C's models
- **Track B** (Anisotropic PDE + Therapy): Supplies the anisotropic diffusion tensor geometry and adaptive therapy policy space that Track C's RL operates within

## Summary

Track C is the most revolutionary because it **translates molecular and biophysical insights into a clinically viable adaptive therapy framework** — with real-patient validation, biomarker-driven stratification, and quantified drug-sparing benefits. It is the track that makes the entire computational platform actionable in a clinical context.